Klinisch orientierter Schwerpunkt
FB 04 - Universitätsmedizin / Johannes Gutenberg-Universität Mainz
Ratzel, Eileen; Gerlach, Christina; Pretzell, Ina et al.
"But you need a Questionnaire Like This": Real Life Experience of Quality of Life Assessment in Outpatients with Lung and Prostate Cancers - A Longitudinal Cohort StudyONCOLOGY RESEARCH AND TREATMENT. Bd. 43. 2020 S. 141-142
Maasberg, Sebastian; Bacher, Maria; Rinke, Anja et al.
"Routine Usage of Molecular Targeted Therapies (Everolimus and Sunitinib) and Temozolomide Based Chemotherapy in Neuroendocrine Neoplasia and Its Outcome"ONCOLOGY RESEARCH AND TREATMENT. Bd. 43. 2020 S. 43-44
Heimes, A. S.; Fries, P.; Stergiou, N. et al.
(TA)MUC1 as a potential new target for breast cancer therapyGEBURTSHILFE UND FRAUENHEILKUNDE. Bd. 80. H. 10. 2020 S. E213-E213
Kropp, Korbinian N.; Schaeufele, Tim J.; Fatho, Martina et al.
A bicistronic vector backbone for rapid seamless cloning and chimerization of alpha beta T-cell receptor sequencesPLOS ONE. Bd. 15. H. 9. 2020
Kaina, Bernd
A genome-wide screening for DNA repair genes: much more players than hitherto knownSIGNAL TRANSDUCTION AND TARGETED THERAPY. Bd. 5. H. 1. 2020
Weissinger, Eva M.; Metzger, Jochen; Schleuning, Michael et al.
A multicenter prospective, randomized, placebo-controlled phase II/III trial for preemptive acute graft-versus-host disease therapyLEUKEMIA. 2020
Lopez, Juanita S.; Camidge, Ross; Iafolla, Marco et al.
A phase Ib study to evaluate RO7198457, an individualized Neoantigen Specific immunoTherapy (iNeST), in combination with atezolizumab in patients with locally advanced or metastatic solid tumorsCANCER RESEARCH. Bd. 80. H. 16. 2020
Fottner, C.; Apostolidis, L.; Ferrata, M. et al.
A Phase II, Open-Label, Multicenter Trial of Avelumab in Patients with Advanced, Metastatic High Grade Neuroendocrine Carcinomas NEC G3 (WHO 2010) Progressive after First-line Chemotherapy (AVENEC)NEUROENDOCRINOLOGY. Bd. 110. 2020 S. 224-224
Borad, Mitesh J.; Bridgewater, John A.; Morizane, Chigusa et al.
A phase III study of futibatinib (TAS-120) versus gemcitabine-cisplatin (gem-cis) chemotherapy as first-line (1L) treatment for patients (pts) with advanced (adv) cholangiocarcinoma (CCA) harboring fibroblast growth factor receptor 2 (FGFR2) gene rearrangements (FOENIX-CCA3)JOURNAL OF CLINICAL ONCOLOGY. Bd. 38. H. 4. 2020
Sellmer, Andreas; Pilsl, Bernadette; Beyer, Mandy et al.
A series of novel aryl-methanone derivatives as inhibitors of FMS-like tyrosine kinase 3 (FLT3) in FLT3-ITD-positive acute myeloid leukemiaEUROPEAN JOURNAL OF MEDICINAL CHEMISTRY. Bd. 193. 2020